Kornimate/medical-research-clean huggingface dataset:
association between erythroferron and perioperative hemoglobin levels in patient undergoing heart valve surgery

Conditions: Postoperative Anemia

Summary: in patients undergoing cardiac surgery, perioperative anemia is an important factor in surgical recovery. in addition to the low preoperative hemoglobin level, the delayed recovery of the postoperative hemoglobin level is an important problem affecting the incidence of postoperative anemia. erythroferron is the early response to of the red blood cell production in stressful situations such as anemia, bleeding, and hypoxia. therefore, it is thought that acute blood loss and systemic inflammatory reaction that inevitably occurs after cardiac surgery will synthesize erythroferron, which helps to restore hemoglobin level at postoperative period by promoting hematopoiesis by simultaneously inhibiting hepcidin and activating hematopoiesis. in this study, the investigators will investigate the association between erythroferron and perioperative hemoglobin levels in patient undergoing heart valve surgery.


Eligibility criteria:
inclusion criteria: * patients older than 20 years * undergoing elective valvular heart surgery exclusion criteria: * emergency operation * co-operation with other surgeries * patients with cardiogenic shock or ventricular-assist device (eg. ecmo, iabp) * patients requiring mechanical ventilator care in preoperative period * patient with severe chronic kidney disease (gfr(ckd-epi) \<30ml/min/1.73m2) * patients with preoperative infection status (eg. sepsis) * patients with acute bleeding status * hemoglobin concentration below 10g/dl * disease directly affecting hematopoiesis (eg. leukemia, myeloma, aplastic anemia) * uncompensated liver cirrhosis, acute hepatitis, alcoholics * patients who participated in other clinical studies that could affect prognosis * patients who cannot understand the informed consent (eg. foreigner)
short-term transcutaneous or epidural spinal stimulation for enabling motor function in humans with sci

Conditions: Paraplegia; Tetraplegia; Paralysis; Quadraplegia

Summary: a study comparing short-term delivery of epidural spinal stimulation versus transcutaneous spinal stimulation.

the purpose of this study is to compare spinal motor nerve response to electrical stimulation delivered directly to the epidural space, and delivered through the skin (transcutaneously), and to measure any changes in motor performance over the course of about 5 months, during and after using one of the two types of stimulation.

Eligibility criteria:
inclusion criteria: * spinal cord injury due to trauma located at or above the tenth thoracic vertebrae (t10) * american spinal injury association grading scale of a-d (2 from each) below the level of sci * intact spinal reflexes below the level of sci * at least 1-year post-sci * at least 22 years of age * willing to use medically acceptable methods of contraception, if female and of child-bearing potential exclusion criteria: * currently a prison inmate, or awaiting trial, related to criminal activity * pregnancy at the time of enrollment * history of chronic and/or treatment resistant urinary tract infection * unhealed decubitus ulcer * unhealed skeletal fracture * untreated clinical diagnosis of depression * undergoing, or planning to undergo, diathermy treatment * active participation in another interventional clinical trial * presence of conditions or disorders which require mri monitoring * a history of coagulopathy or other significant cardiac or medical risk factors for surgery * current use of a ventilator * clinically diagnosed cardiopulmonary complications such as chronic obstructive pulmonary disease, cardiac failure, or heart arrhythmia that contraindicate changes in body position such as supine-to-sit-to-stand activities, prolonged standing, or stepping * history of frequent hypotension characterized by light headedness, or loss of consciousness * history of frequent hypertension characterized by headache, or bradycardia * history of frequent, severe, autonomic dysreflexia * any illness or condition which, based on the research team's assessment, will compromise with the patient's ability to comply with the protocol, patient safety, or the validity of the data collected during this study.
chronic pain after lung transplantation, an incidence study

Conditions: Lung Transplantation

Summary: this is an investigation on the frequency of chronic pain amongst recipients after lung transplantation. factors relating to the development of chronic pain are investigated.


Eligibility criteria:
inclusion criteria: * able to understand and give consent * can read * residing in denmark exclusion criteria: * unable to understand the written information in danish * abuse (medicine, drugs, alcohol) * severe psychiatric illness * conflicting neurological disease

Keywords: lung transplantation chronic pain thoracotomy
total knee arthroplasty biomechanics

Conditions: Total Knee Arthroplasty (TKA)

Summary: in total knee arthroplasty (tka), the relationship between implant design, soft tissue balance, neuromuscular contributions, and rehabilitation strategies on patient satisfaction and functional outcomes is highly complex and poorly understood. the investigators will prospectively study the effects of these factors using in vivo assessments preoperatively, and postoperatively. computer simulation models will also be used to analyze lower extremity biomechanics.

total knee arthroplasty (tka) is the primary treatment for end-stage knee osteoarthritis and effectively relieves pain and improves function after surgery. nevertheless, as many as 1 in 5 patients are dissatisfied with the postoperative outcome, and knee instability remains one of the top indications for revision surgery. implant design, soft tissue balance, neuromuscular capabilities, and rehabilitation strategies can all influence postoperative outcomes. however, the relationship between these factors and the most effective therapeutic approach for total knee arthroplasty has yet to be identified. the investigators will study preoperative and postoperative functional measures and patient satisfaction along with implant design and specific intraoperative data, which may help inform a targeted approach for optimal outcomes after total knee arthroplasty and improve future care of patients.

Eligibility criteria:
inclusion criteria: * patients requiring unilateral tka for knee osteoarthritis * no osteoarthritis symptoms in contralateral knee * radiographic coronal deformity ≤ 15° * preoperative flexion ≥ 90° * receiving one of four implants used by uf orthopaedic surgeons * able to walk for a short distance without the use of ambulatory aids * healthy participants: 1. age 49-85 years 2. healthy with no signs or symptoms of lower limb arthritis or injury 3. able to walk for a short distance without the use of ambulatory aids exclusion criteria: * bmi \> 40 kg/m2 * presence of knee, hip, or ankle prosthesis for either limb * presence of hip prosthesis in surgical limb (tka only subjects) * history of lower limb or spinal surgery within the last year * presence of neurologic or orthopaedic disorders that could affect gait or balance * chronic opioid or illicit drug use * poorly controlled diabetes (hba1c \> 7 percent) * chronic pain syndrome * chronic back pain * presence of vestibular disorder * pregnancy

Keywords: knee osteoarthritis rehabilitation strategies soft tissue balance
a study to measure the level of drug in nasal tissue and blood after taking a single 2g dose or 500mg tablets for up to

Conditions: Sinusitis

Summary: to measure the level of drug in nasal tissue and blood after taking a single 2g dose or 500mg tablets for up to 3 days.


Eligibility criteria:
inclusion criteria: * subjects considered by the principal investigator as an appropriate candidate for endoscopic sinus surgery, e.g., for the removal of the thickened and diseased mucosal tissue that blocks the ostiomeatal complex (omc). exclusion criteria: * known or suspected hypersensitivity or intolerance to any macrolide-like compound, including erythromycin, clarithromycin, azithromycin or telithromycin.
irinotecan for previously treated, advanced, non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer

Summary: certain genetic factors can affect a patient's potential sensitivity to therapeutic drugs and other agents. there is a factor called isg15 which might help doctors better identify patients with advanced non-small cell lung cancer (nsclc) whose tumors may be more sensitive to the drug called irinotecan. this factor is elevated in roughly 30% of nsclc cases. irinotecan is an agent that inhibits the enzyme called topoisomerase i that is involved in cell growth, and it has been fda approved for 17 years for another type of cancer.

the goal of this trial is to demonstrate the potential clinical benefit of targeted irinotecan chemotherapy in nsclc patients whose tumors display a specific phenotype that is associated with increased sensitivity to this drug, isg15h.

Eligibility criteria:
inclusion criteria: -inclusion: 18 years of age or older have received prior chemotherapy for histologically proven advanced non-small cell lung cancer, up to 3 prior treatments tumors display high isg15 (isg15h) at screening life expectancy of at least 12 weeks ecog/zubrod performance status of 0-2 provide informed consent permission to participate adequate bone marrow function as follows: 1. absolute neutrophil count of greater than or equal to 1,500 or cells/mm3, and 2) platelet count greater than or equal to 100,000/mm3 and 3) absence of a regular red blood cell transfusion requirement adequate hepatic function with: 1. total bilirubin less than or equal to 4.0 mg/dl, and 2. sgot or sgpt less than or equal to four times uln adequate renal function as defined by: 1) serum creatinine less than or equal to 1.5 x uln exclusion criteria: symptomatic brain metastases pregnant women or nursing mothers patients of child bearing potential must use adequate contraception. may not be receiving other concurrent chemotherapy or radiation therapy severe medical problems such as uncontrolled diabetes mellitus or cardiovascular disease or active infections previous hypersensitivity reaction to camptothecins

Keywords: lung non small cell nsclc irinotecan
radiation therapy before surgery in treating patients with hormone receptor positive, her2 negative breast cancer

Conditions: Estrogen Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Progesterone Receptor Positive

Summary: this phase ii trial studies how well radiation therapy before surgery works in treating patients with hormone receptor positive, her2 negative breast cancer. radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. giving radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

primary objectives: i. to evaluate the change in percent tumor-infiltrating lymphocytes (til) as a continuous variable before and after preoperative boost radiotherapy (rt) in hormone receptor (hr)+/human epidermal growth factor receptor2 (her2)- breast cancers. secondary objectives: i. to evaluate the safety of preoperative boost rt administered to patients with hr+/her2- breast cancer. exploratory objectives: * i. to assess the mechanisms of cell death induced by preoperative boost rt. * ii. to assess immunologic and molecular responses to preoperative boost rt. * iii. to assess the correlations between immune markers, cell death markers, and their changes during treatment. * iv. to determine if magnetic resonance imaging (mri) can be used to predict breast tumor response to neoadjuvant radiation. outline: patients undergo boost radiation therapy 6-8 days before breast surgery. after surgery, patients continue to receive standard of care radiation therapy. after completion of study treatment, patients are followed up at 6 months.

Eligibility criteria:
inclusion criteria: inclusion: * age \>/=18 years at time of study entry * histologically confirmed hr+/her2- (according to american society of clinical oncology/college of american pathologists guidelines) invasive carcinoma of the breast * presence of a clip in the primary breast cancer * biopsy-amenable residual disease in the breast measuring \>/= 1cm in at least one dimension on ultrasound cm in at least one dimension on ultrasound * eastern cooperative oncology group (ecog) performance status of 0-1 * signed written informed consent * planned for multidisciplinary evaluation by a breast surgical oncologist and breast radiation oncologist. for patients undergoing mastectomy and desirous of reconstruction or those undergoing breast conservation in whom oncoplastic local tissue rearrangement or reduction mammoplasty is being considered, this multidisciplinary evaluation will also include a plastic surgeon. exclusion: * women who are pregnant or breast-feeding * contraindication to receive radiotherapy
animation-based breathing therapy for school-age children

Conditions: Children; Breathing Patterns; Stress; School Health

Summary: this randomized controlled trial aims to investigate the efficacy of animation-based breathing therapy on the physical (cough strength, chest expansion, and walking speed) and psychological health (perceived stress level, well-being, and attention) of school-age children.

one hundred thirty school-age children, aged between 8 and 12, will be randomly assigned to one of two groups: an animation-based breathing therapy group or a control group. the intervention group will receive animation-based breathing therapy for six weeks (two sessions per day, five days per week). assessments will be conducted at baseline and at the end of the six-week period. cough strength will be measured using a peak expiratory flow meter. chest expansion will be assessed with a measuring tape at the axillary, epigastric, and subcostal levels. walking speed will be evaluated using the 10-meter walk test. perceived stress will be assessed using the perceived stress scale for children, well-being will be measured using the who-5 child wellbeing index, and attention will be assessed using the bourdon attention test.

Eligibility criteria:
inclusion criteria: -- children aged between 8 and 12 years, * attending school and formal education regularly, * volunteers whose parents and themselves agreed to participate after being informed about the purpose of the study and the procedures involved, and who provided written informed consent. exclusion criteria: * children with any condition that may prevent them from completing self-reported questionnaires during the assessment (e.g., difficulty in understanding forms, physical disabilities, illiteracy), * history of any upper or lower extremity injury within the past six months, * history of any upper or lower extremity surgery within the past six months, * presence of any soft tissue disorder, * diagnosed with serious gastrointestinal, cardiovascular, pulmonary, or hematological disorders following examination by a specialist physician, * diagnosed spinal problems such as scoliosis, kyphosis, or kyphoscoliosis, * diagnosed with psychotic disorder, bipolar disorder, or autism spectrum disorder, * history of epilepsy or serious head trauma, * current use of psychotropic medications.

Keywords: children breathing stress school well-being
the effect of hyaluronic acid for carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: carpal tunnel syndrome (cts) is the most common peripheral entrapment neuropathy with involving compression of the median nerve in the carpal tunnel. rather than other progressive disease, cts is characterized by remission and recurrence. the hydrodissection could decrease the entrapment of nerve to restore blood supply. in addition, the hyaluronic acid was proved to decrease adhension of soft tissue and nerve during operation. the investigators design a randomized, double-blind, controlled trial to assess the effect after ultrasound-guided hydrodissection with hyaluronic acid in patients with cts.

after obtaining written informed consent, patients with bilateral cts will been randomized into intervention and control group. participants in intervention group received one-dose ultrasound-guided hydrodissection with hyaluronic acid and control side received one-dose ultrasound-guided injection with normal saline. no additional treatment after injection through the study period. the primary outcome is boston carpal tunnel syndrome questionnaire (bctq) and secondary outcomes include visual analog scale (vas), cross-sectional area (csa) of the median nerve, sensory nerve conduction velocity of the median nerve, and finger pinch strength. the evaluation was performed pretreatment as well as on the 2nd week, 1st, 3rd, 6th month and one year after the treatment.

Eligibility criteria:
inclusion criteria: * age between 20-80 year-old. * diagnosis was confirmed using an electrophysiological study exclusion criteria: * cancer * coagulopathy * pregnancy * inflammation status * cervical radiculopathy * polyneuropathy, brachial plexopathy * thoracic outlet syndrome * previously undergone wrist surgery or steroid injection for cts

Keywords: hydrodissection hyaluronic acid
interleukin- 17 (il-17), bcl-3, and nf-kappa-b inhibitor zeta (iκbζ) expression levels in the psoriasis patients

Conditions: Psoriasis; Periodontal Diseases

Summary: this study aimed to compare the levels of il-17 (interleukin- 17), bcl-3 (b-cell lymphoma 3-encoded protein), and iκbζ (nf-kappa-b inhibitor zeta) in the gingival crevicular fluid of psoriatic and healthy individuals and the clinical parameters such as periodontal health, gingival index, plaque index and mobility (using periotest device)in the patient and control groups.

patient selection ten patients previously diagnosed with psoriasis who visited the van 100. yıl university faculty of dentistry oral and maxillofacial radiology dental clinic were included in the study. non-psoriasis individuals were selected from volunteer patients attending the same dental clinic. clinical measurements a periodontist conducted the periodontal evaluation, which included a comprehensive assessment of clinical periodontal status, a full mouth manual periodontal charting, measurement of probing depth, clinical attachment level, bleeding on probing, and evaluation of mobility using a periotest device. additionally, information regarding the patient's smoking status, frequency of smoking, and oral hygiene habits was obtained. gingival crevicular fluid (gcf) collection samples were taken from two mandibular molar teeth. before sampling, the sites were isolated with cotton rolls and then carefully dried with an air syringe to avoid saliva contamination. gcf was collected using sterile periodontal strips by gently inserting them into the gingival sulcus or pocket until slight resistance was noticed. after 30 s, the strips were collected into sterile tubes and immediately transported to the laboratory for storage (-40 °c) and posterior analysis.

Eligibility criteria:
inclusion criteria: * patients previously diagnosed with psoriasis * adults who are 18 years of age or older * patients having at least 11 teeth exclusion criteria: * patients with any known systemic disease other than psoriasis * patients who had received antibiotic, nonsteroidal anti-inflammatory, and/or immunomodulatory therapy within the last three months * patients who had received radiotherapy and/or chemotherapy within the last years

Keywords: psoriasis gene expression periodontal health
toripalimab combined with radiotherapy and chemotherapy in the treatment of snmm after endoscopic surgery

Conditions: Malignant Melanoma; Sinonasal Melanoma

Summary: phase ii, single-arm, prospective clinical study of toripalimab(a pd-1 antibody) combined with radiotherapy and chemotherapy in the treatment of sinonasal malignant mucosal melanoma after endoscopic surgery.


Eligibility criteria:
inclusion criteria: 1.pathologically diagnosed as sinonasal malignant mucosal melanoma, locally resectable and no contraindication for surgery or radiation. 2.t3 and t4. 3.age ≥18 year-old 4.no distant metastasis 5.no head and neck radiation and systemic anti-tumor therapy performed in the past 5 years. 6.the performance status of the eastern cooperative oncology group(ecog) is 0-2 points and surgery after general anesthesia and postoperative radiation could be tolerated. 7.accepted organ function exclusion criteria: 1. patients who refused to sign informed consent. 2. have received radioactive seed implantation in the treatment area. 3. suffer from uncontrolled disease which could interfere treatment. 4. suffered from another malignant tumor or multiple primary tumors at the same time within 5 years (excluding fully treated basal cell or squamous cell skin cancer, cervical cancer in situ, etc.). 5. the patient has surgical contraindications: such as severe cardiopulmonary disease, coagulation dysfunction and so on. 6.the patients have autoimmune diseases. 7. the patient is using immunosuppressive agents or systemic hormone therapy to achieve the purpose of immunosuppression (dose\>10mg/day prednisone or other curative hormones), and continues to use it within 2 weeks before the first administration; 8. severe allergic reaction to other monoclonal antibodies; 9. previously received pd-1 monoclonal antibody, ctla-4 monoclonal antibody (or any other antibody that acts on t cell co-stimulation or checkpoint pathway) treatment; 10. live vaccines have been inoculated within 4 weeks before the first administration or during the study period; 11. the patient has any situation that may hinder study compliance or the safety during the study period.12. existence of serious neurological or psychiatric diseases, such as dementia and seizures; 13. uncontrolled active infection. 14. pregnant or breastfeeding women. 15. those who have no personal freedom and independent capacity for civil conduct;p. 16. there are other situations that are not suitable for entry into the study.
telemedicine follow-up for post-acs patients

Conditions: ACS - Acute Coronary Syndrome

Summary: the aim is to compare the safety of using telemedicine and office visit follow-up in post-acute coronary syndrome patients

rehabilitation after acute coronary syndrome includes visits to the cardiologist's office at 1, 2, 6 and 12 months after discharge. due to the covid-19 pandemic, visiting a cardiologist's office maybe impossible. in such cases telemedicine follow-up visit would be reasonable choice. taking into account the absence of studies in this area, providing investigation evaluating parameters of safety for both methodics is relevant.

Eligibility criteria:
inclusion criteria: 1. signed informed consent 2. age ≥ 40 years 3. pci with coronary artery stenting for acs 4. angiographic success pci exclusion criteria: 1. patients with cancer 2. severe chf (ef lv \<35% or functional class of heart failure iii-iv nyha) 3. severe valvular heart disease or prosthetic heart valves. 4. severe forms of ckd (gfr\<30ml/min) 5. planned staged revascularization during the next 12 months 6. planned surgery within the next 12 months

Keywords: telemedicine follow-up visit post-acs rehabilitation
a safety, tolerability, and efficacy study of vc-01™ combination product in subjects with type i diabetes mellitus

Conditions: Type 1 Diabetes Mellitus

Summary: the purpose of this trial is to test if vc-01™ combination product can be implanted subcutaneously in subjects with type 1 diabetes and maintained safely for two years. it will also test if vc-01 is an effective treatment for subjects with type 1 diabetes.


Eligibility criteria:
inclusion criteria: * men and women (non-pregnant and non-childbearing potential) * diagnosis of type 1 diabetes mellitus for at least 3 years * stable diabetic treatment * willingness to use a continuous glucose meter * acceptable candidate for implantation exclusion criteria: * advanced complications associated with diabetes * immunosuppressive therapy